| scholarly article | Q13442814 |
| review article | Q7318358 |
| P2093 | author name string | Paul Anantharajah Tambyah | |
| Evelyn Xiu Ling Loo | |||
| Elizabeth Huiwen Tham | |||
| Alicia Yi Hui Kang | |||
| Hui Xing Lau | |||
| Lydia Su Yin Wong | |||
| P2860 | cites work | Molecular mechanism for antibody-dependent enhancement of coronavirus entry | Q84316178 |
| Clinical characteristics of 24 asymptomatic infections with COVID-19 screened among close contacts in Nanjing, China | Q87461278 | ||
| A Well Infant with Coronavirus Disease 2019 (COVID-19) with High Viral Load | Q87461326 | ||
| Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? | Q87812699 | ||
| The imbalance of Th17/Th1/Tregs in patients with type 2 diabetes: relationship with metabolic factors and complications. | Q45998987 | ||
| Antibody therapies for the prevention and treatment of viral infections. | Q47143843 | ||
| Effects of matrix metalloproteinase inhibitor doxycycline and CD147 antagonist peptide-9 on gallbladder carcinoma cell lines | Q47649561 | ||
| Longitudinal profile of antibodies against SARS-coronavirus in SARS patients and their clinical significance. | Q47653968 | ||
| Good ACE, bad ACE do battle in lung injury, SARS. | Q47752741 | ||
| Angiotensin-converting enzyme 2 protects from severe acute lung failure | Q47768368 | ||
| Lack of association between New Haven coronavirus and Kawasaki disease. | Q47778643 | ||
| Human intestine luminal ACE2 and amino acid transporter expression increased by ACE-inhibitors. | Q48588159 | ||
| Hospitalizations for Kawasaki syndrome among children in the United States, 1997-2007. | Q51140892 | ||
| Inflammatory cytokine profile in children with severe acute respiratory syndrome. | Q51636454 | ||
| ACE and ACE2 activity in diabetic mice. | Q54594958 | ||
| The dominance of human coronavirus OC43 and NL63 infections in infants | Q56795531 | ||
| Expression of elevated levels of pro-inflammatory cytokines in SARS-CoV-infected ACE2+ cells in SARS patients: relation to the acute lung injury and pathogenesis of SARS | Q79218330 | ||
| Disappearance of antibodies to SARS-associated coronavirus after recovery | Q81251115 | ||
| Evolution of the immune system in humans from infancy to old age | Q26772107 | ||
| A systems biology approach to the effect of aging, immunosenescence and vaccine response | Q26994749 | ||
| Ontogeny of early life immunity | Q27000632 | ||
| Structural Insights into the Mechanisms of Antibody-Mediated Neutralization of Flavivirus Infection: Implications for Vaccine Development | Q27488364 | ||
| Inflamm-aging. An evolutionary perspective on immunosenescence | Q28141817 | ||
| Antibody-dependent enhancement of viral infection: molecular mechanisms and in vivo implications | Q28185515 | ||
| IgG antibodies to dengue enhanced for FcγRIIIA binding determine disease severity | Q33438726 | ||
| Aging of the innate immune system | Q33666891 | ||
| Targeting Coronaviral Replication and Cellular JAK2 Mediated Dominant NF-κB Activation for Comprehensive and Ultimate Inhibition of Coronaviral Activity | Q33826034 | ||
| Antibody and virus: binding and neutralization | Q33895369 | ||
| Chronic inflammation (inflammaging) and its potential contribution to age-associated diseases | Q34040980 | ||
| Antibody-dependent SARS coronavirus infection is mediated by antibodies against spike proteins | Q34041594 | ||
| Antibody-Dependent Enhancement of Virus Infection and Disease | Q35119221 | ||
| Changes in Healthy Human IgG Fc-Glycosylation after Birth and during Early Childhood. | Q36012882 | ||
| Seroepidemiology of group I human coronaviruses in children | Q36178577 | ||
| Role of the renin-angiotensin system in ventilator-induced lung injury: an in vivo study in a rat model | Q36225758 | ||
| Early-life compartmentalization of human T cell differentiation and regulatory function in mucosal and lymphoid tissues | Q36436829 | ||
| ACE inhibitors - angiotensin II receptor antagonists: A useful combination therapy for ischemic heart disease | Q36726341 | ||
| Severe acute respiratory syndrome (SARS) coronavirus-induced lung epithelial cytokines exacerbate SARS pathogenesis by modulating intrinsic functions of monocyte-derived macrophages and dendritic cells | Q37127923 | ||
| Age-associated decrease in TLR function in primary human dendritic cells predicts influenza vaccine response | Q37401759 | ||
| Angiotensin-converting enzyme 2 (ACE2) in disease pathogenesis | Q37687743 | ||
| The impact of differential antiviral immunity in children and adults | Q38037339 | ||
| Unravelling the human genome-phenome relationship using phenome-wide association studies. | Q38732876 | ||
| A regulatory loop involving miR-22, Sp1, and c-Myc modulates CD147 expression in breast cancer invasion and metastasis | Q38987438 | ||
| Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology | Q39279748 | ||
| Human T cell immunosenescence and inflammation in aging | Q39451386 | ||
| OC43 strain-related coronavirus antibodies in different age groups | Q39684040 | ||
| Human coronavirus NL63 and 229E seroconversion in children | Q39762396 | ||
| Examination of seroprevalence of coronavirus HKU1 infection with S protein-based ELISA and neutralization assay against viral spike pseudotyped virus | Q39864776 | ||
| Prior immunization with severe acute respiratory syndrome (SARS)-associated coronavirus (SARS-CoV) nucleocapsid protein causes severe pneumonia in mice infected with SARS-CoV. | Q39926740 | ||
| Neutralization of Virus Infectivity by Antibodies: Old Problems in New Perspectives | Q40295939 | ||
| Immunodominant SARS Coronavirus Epitopes in Humans Elicited both Enhancing and Neutralizing Effects on Infection in Non-human Primates | Q40540668 | ||
| Inflammaging and the Lung | Q41989657 | ||
| Possible involvement of infection with human coronavirus 229E, but not NL63, in Kawasaki disease | Q42218066 | ||
| SARS-coronavirus modulation of myocardial ACE2 expression and inflammation in patients with SARS. | Q44282005 | ||
| Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome. | Q44805074 | ||
| Association between a novel human coronavirus and Kawasaki disease | Q45003164 | ||
| SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor | Q88292103 | ||
| Influenza in temperate and tropical Asia: a review of epidemiology and vaccinology | Q89526703 | ||
| Understanding SARS-CoV-2-Mediated Inflammatory Responses: From Mechanisms to Potential Therapeutic Tools | Q89993478 | ||
| Unique epidemiological and clinical features of the emerging 2019 novel coronavirus pneumonia (COVID-19) implicate special control measures | Q90060949 | ||
| Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China | Q90251707 | ||
| Laboratory abnormalities in children with novel coronavirus disease 2019 | Q90330011 | ||
| SARS-CoV-2 Infection in Children | Q90429164 | ||
| Coronavirus Disease 2019 (COVID-19) and Cardiovascular Disease | Q90571136 | ||
| Systematic review of COVID-19 in children shows milder cases and a better prognosis than adults | Q90583807 | ||
| Case-Fatality Rate and Characteristics of Patients Dying in Relation to COVID-19 in Italy | Q90595119 | ||
| Severe Outcomes Among Patients with Coronavirus Disease 2019 (COVID-19) - United States, February 12-March 16, 2020 | Q90664174 | ||
| Diabetes is a risk factor for the progression and prognosis of COVID-19 | Q90788181 | ||
| Kawasaki disease: guidelines of the Italian Society of Pediatrics, part I - definition, epidemiology, etiopathogenesis, clinical expression and management of the acute phase | Q91206521 | ||
| The Dilemma of Coronavirus Disease 2019, Aging, and Cardiovascular Disease: Insights From Cardiovascular Aging Science | Q91528609 | ||
| Effectiveness of convalescent plasma therapy in severe COVID-19 patients | Q91611037 | ||
| Is antibody-dependent enhancement playing a role in COVID-19 pathogenesis? | Q91988021 | ||
| ACE2/Angiotensin 1-7 protective antiinflammatory and antioxidant role in hyperoxic lung injury: support from studies in Bartter's and Gitelman's syndromes | Q92082960 | ||
| The potential danger of suboptimal antibody responses in COVID-19 | Q92130769 | ||
| Angiotensin-converting enzyme 2 attenuates inflammatory response and oxidative stress in hyperoxic lung injury by regulating NF-κB and Nrf2 pathways | Q92496313 | ||
| Aging and the Immune System: the Impact of Immunosenescence on Viral Infection, Immunity and Vaccine Immunogenicity | Q92540693 | ||
| Single-cell landscape of bronchoalveolar immune cells in patients with COVID-19 | Q94600823 | ||
| Expression of the SARS-CoV-2 Entry Proteins, ACE2 and TMPRSS2, in Cells of the Olfactory Epithelium: Identification of Cell Types and Trends with Age | Q94604936 | ||
| An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: an observational cohort study | Q94919190 | ||
| Exploring Diseases/Traits and Blood Proteins Causally Related to Expression of ACE2, the Putative Receptor of SARS-CoV-2: A Mendelian Randomization Analysis Highlights Tentative Relevance of Diabetes-Related Traits | Q95272307 | ||
| Nasal Gene Expression of Angiotensin-Converting Enzyme 2 in Children and Adults | Q95307511 | ||
| Why does COVID-19 disproportionately affect older people? | Q96018992 | ||
| Clinical Characteristics of 58 Children With a Pediatric Inflammatory Multisystem Syndrome Temporally Associated With SARS-CoV-2 | Q96224302 | ||
| COVID-19 - Does This Disease Kill Due to Imbalance of the Renin Angiotensin System (RAS) Caused by Genetic and Gender Differences in the Response to Viral ACE 2 Attack? | Q96619468 | ||
| Multisystem Inflammatory Syndrome in Children in New York State | Q96772063 | ||
| Multisystem Inflammatory Syndrome in U.S. Children and Adolescents | Q96772068 | ||
| Systems-Level Immunomonitoring from Acute to Recovery Phase of Severe COVID-19 | Q98663509 | ||
| P921 | main subject | Betacoronavirus | Q16532287 |
| immunosenescence | Q1660191 | ||
| antibody-dependent enhancement | Q1662341 | ||
| cytokine release syndrome | Q3961647 | ||
| coronavirus disease | Q18975243 | ||
| broadly neutralizing antibody | Q56298097 | ||
| age factor | Q64705711 | ||
| SARS-CoV-2 | Q82069695 | ||
| P577 | publication date | 2020-08-27 | |
| P1433 | published in | The Journal of Allergy and Clinical Immunology: In Practice | Q24056070 |
| P1476 | title | Age-Related Differences in Immunological Responses to SARS-CoV-2 |
Search more.